For routine prophylaxis in adults and children 6 years and older with hemophilia A or B, with or without inhibitors†
Only HYMPAVZI is a once-weekly fixed-dose‡ pen with proven bleed protection* and demonstrated safety§
A set dose comes in each pen, so you don't need to mix or measure
Once-weekly dosing designed to fit into your schedule
Injected under the skin, not into a vein
*In the phase 3 BASIS study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds vs on-demand factor-based treatment without inhibitors, vs factor-based prophylaxis without inhibitors, and vs on-demand bypassing treatment with inhibitors after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment without inhibitors (3.2 ABR vs 39.9 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment without inhibitors (5.1 ABR vs 7.9 ABR). 93% reduction in treated bleeds on HYMPAVZI compared with on-demand bypass treatment with inhibitors (1.4 ABR vs 19.8 ABR). Secondary objectives measured the ABR of treated joint bleeds, treated target joint bleeds, treated spontaneous bleeds, and total bleeds (treated and untreated). 92% reduction in joint bleeds on HYMPAVZI compared with on-demand factor-based treatment without inhibitors (2.9 ABR vs 34.5 ABR). 27% reduction in joint bleeds on HYMPAVZI compared with routine prophylaxis treatment without inhibitors (4.1 ABR vs 5.7 ABR). 93% reduction in joint bleeds on HYMPAVZI compared with on-demand bypass treatment with inhibitors (1.1 ABR vs 15.2 ABR). 92% reduction in target joint bleeds on HYMPAVZI compared with on-demand factor-based treatment without inhibitors (1.8 ABR vs 24.4 ABR). 26% reduction in target joint bleeds on HYMPAVZI compared with routine prophylaxis treatment without inhibitors (2.5 ABR vs 3.4 ABR). 87% reduction in target joint bleeds on HYMPAVZI compared with on-demand bypass treatment with inhibitors (0.8 ABR vs 6.3 ABR). 92% reduction in spontaneous bleeds on HYMPAVZI compared with on-demand factor-based treatment without inhibitors (2.5 ABR vs 32.6 ABR). 36% reduction in spontaneous bleeds on HYMPAVZI compared with routine prophylaxis treatment without inhibitors (3.8 ABR vs 5.9 ABR). 94% reduction in spontaneous bleeds on HYMPAVZI compared with on-demand bypass treatment with inhibitors (0.9 ABR vs 15.3 ABR). 85% reduction in total bleeds on HYMPAVZI compared with on-demand factor-based treatment without inhibitors (7.4 ABR vs 50.0 ABR). 33% reduction in total bleeds on HYMPAVZI compared with routine prophylaxis treatment without inhibitors (6.0 ABR vs 8.9 ABR). 84% reduction in total bleeds on HYMPAVZI compared with on-demand bypass treatment with inhibitors (4.4 ABR vs 27.3 ABR). In the phase 3 BASIS KIDS study, the primary objective was to measure ABR of treated bleeds in patients with and without inhibitors for 12 months. Patients ages 6 to less than 18 without inhibitors taking HYMPAVZI had an ABR of 1.8. Patients ages 6 to less than 18 with inhibitors taking HYMPAVZI had an ABR of 1.4. Secondary objectives measured the ABR of treated joint bleeds, treated target joint bleeds, treated spontaneous bleeds, and total bleeds (treated and untreated). Patients without inhibitors ages 6 to less than 18 taking HYMPAVZI had an ABR of 1.0 for treated joint bleeds, an ABR of 0.2 for treated target joint bleeds, and ABR of 0.8 for treated spontaneous bleeds and an ABR of 2.5 for total bleeds (treated and untreated). Patients with inhibitors ages 6 to less than 18 taking HYMPAVZI had an ABR of 1.2 for treated joint bleeds, an ABR of 0.9 for treated target joint bleeds, and ABR of 1.1 for treated spontaneous bleeds and an ABR of 1.6 for total bleeds (treated and untreated). Individual results may vary.
†It is not known if HYMPAVZI is safe and effective in people receiving ongoing Immune Tolerance Induction (ITI). It is not known if HYMPAVZI is safe and effective in children younger than 6 years of age.
‡For children ages 6 to less than 12, the first dose (loading dose) is 150 mg on day 1. Then a weekly (maintenance) dose of 75 mg as prescribed by your healthcare provider. For adults and adolescents 12+, the first dose (loading dose) is 300 mg on day 1. Then a weekly (maintenance) dose of 150 mg as prescribed by your healthcare provider. If more than 1 injection is required to deliver a complete dose, administer each injection at a different site.
§In the BASIS and BASIS KIDS studies, the most common adverse reactions included injection site reactions, headache, pyrexia, arthralgia, diarrhea, pruritus, and rash.
Proven bleed protection with HYMPAVZI*
Treated bleeds
Joint bleeds
Target joint bleeds
Spontaneous bleeds
Total bleeds
in people living with hemophilia ages 12+ without inhibitors, compared to factor based on-demand treatment and prophylactic factor-based treatment
Understanding novel non-factor treatment options
Download for details about HYMPAVZI and other approved non-factor prophylactic hemophilia treatments.
Real patient story
Meet Peter and see how once-weekly HYMPAVZI fits into his lifestyle.
Savings program
You may pay as little as $0 for HYMPAVZI if you have commercial insurance and meet the eligibility requirements.§
§Eligibility required. Individual savings limited to $15,000 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and conditions apply.
Want the lowdown on HYMPAVZI?
Sign up for more information, including educational tools and updates
